Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
Advertisement
SureTrader Stock Hero Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator binks, Seel
Search This Board:
Last Post: 3/27/2015 4:04:05 PM - Followers: 123 - Board type: Free - Posts Today: 3



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Idera Pharma medical chief bids adieu 03/23/2015 10:44:34 AM
IDRA News: Current Report Filing (8-k) 03/23/2015 07:10:01 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 03/19/2015 04:29:46 PM
IDRA News: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Provides Corporate Update 03/12/2015 08:15:00 AM
IDRA News: Annual Report (10-k) 03/12/2015 07:36:52 AM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1661   will likely pick up some more shares early rivervalley 03/27/15 04:04:05 PM
#1660   Well I'm sitting really, really heavy right here TheHound 03/27/15 03:56:10 PM
#1659   Looks like we're going to test $3.30 again..... TheHound 03/27/15 10:18:22 AM
#1658   Thank you Citrati! Laughter soothes investing pains! Seel 03/26/15 01:28:53 PM
#1657   Bottom right here at $3.30. Next leg up. TheHound 03/26/15 12:30:23 PM
#1656   Ouch. The pain... Stop the pain! TheHound 03/26/15 11:44:42 AM
#1655   weve all been there binks 03/25/15 10:56:24 PM
#1654   LOL, humility becomes you. No disputing your status Citrati 03/25/15 10:05:21 PM
#1653   Always dips after I buy...or, if I make Seel 03/25/15 09:45:02 PM
#1652   Wise. TheHound 03/25/15 07:55:32 PM
#1651   Got in at $3.52 DCA today. I like Canoepaddler 03/25/15 07:44:50 PM
#1650   maybe I'm viewing the video wrong but isn't rivervalley 03/25/15 05:30:33 PM
#1649   * * $IDRA Video Chart 03-25-15 * * ClayTrader 03/25/15 04:58:59 PM
#1648   I jumped back in today @ 4.50. I Randolph Duke 03/25/15 04:47:42 PM
#1647   I was not expecting this this low binks 03/25/15 04:44:47 PM
#1646   back in with a few 3.53 and may rivervalley 03/25/15 04:00:57 PM
#1645   $3.4s not attractive enough? What price are you expecting? stocking4ms 03/25/15 03:58:37 PM
#1644   Still waiting for entry. binks 03/25/15 03:51:12 PM
#1643   Tagged 3.43 the Dec low. Citrati 03/25/15 03:14:08 PM
#1642   took profit on this trade at 3.66. Surprised rivervalley 03/25/15 02:31:11 PM
#1641   In for the day at $3.51 TheHound 03/25/15 01:46:39 PM
#1640   traded this one a few times before and rivervalley 03/25/15 01:28:42 PM
#1639   IBB getting whacked big time. -11.50 ish Citrati 03/25/15 12:15:09 PM
#1638   Naw....I bought more at 3.85. That totally THEPK5 03/25/15 11:22:08 AM
#1637   Here we are. Testing that previous low. Stop Citrati 03/25/15 11:00:57 AM
#1636   LoL. Now that you have them, may we TheHound 03/25/15 10:22:05 AM
#1635   Great to get in in the 3s. Seel 03/24/15 04:42:06 PM
#1634   Got my $3.98s. Wish I'd held on Black sunshine 03/23/15 08:19:49 PM
#1633   Yup. That is a real concern. Should allow Seel 03/23/15 06:22:52 PM
#1632   he joined jan 9th 2014 yea so a camacho 03/23/15 04:46:38 PM
#1631   Yeah, agree with that. Possibly, they just made Citrati 03/23/15 04:38:44 PM
#1630   That's not normally something I would see as positive binks 03/23/15 04:27:24 PM
#1629   On March 17, 2015, Louis Brenner, M.D. resigned Citrati 03/23/15 04:04:27 PM
#1628   Very possible this is a bottom. Odds about Citrati 03/23/15 10:21:07 AM
#1627   My jowls are dripping with drool...... TheHound 03/23/15 10:05:56 AM
#1626   Yuppers Still sitting on the sidelines though binks 03/23/15 10:04:33 AM
#1625   There's your $3's. GL Citrati 03/23/15 09:54:07 AM
#1624   Binks, probably right....6 month daily puts the odds Citrati 03/21/15 01:24:44 AM
#1623   may yet get those 3s binks 03/20/15 10:23:23 PM
#1622   Another point of entry coming. Wait for the signal. Citrati 03/20/15 03:26:37 PM
#1621   thnx for that my friend. Did broadfin buy camacho 03/18/15 05:23:00 AM
#1620   The IDRA purchase by Baker Bro for $20million Citrati 03/17/15 10:22:54 PM
#1619   could i get some help deciphering exactly what camacho 03/17/15 04:53:23 AM
#1618   Nice volume buying stepped in. Those 20 purchases Citrati 03/17/15 12:45:53 AM
#1617   Update of last post. Citrati 03/13/15 12:57:13 PM
#1616   4 bucks is definitely in play here. FFS TheHound 03/12/15 12:39:00 PM
#1615   IMO both the 2 month chart with fast Citrati 03/11/15 06:14:49 PM
#1614   I do too. And will be buying more Seel 03/11/15 05:58:18 PM
#1613   I think it can definitely hit the 3's binks 03/11/15 04:17:55 PM
#1612   Think it will hit 3.75 this round? noretreat 03/11/15 04:04:34 PM
PostSubject